Industry symposia

17 September 2022, Saturday

Title COVID-19 Vaccine Effectiveness: Myths vs RWE. Are Current Vaccines Optimal to Protect the Most Vulnerable?
ASVAC 2022
Details Date: 17th September 2022
Time: 1045 – 1145 hrs, IST time (GMT +5.30)
Synopsis As the COVID-19 pandemic enters the third year and is transitioning into an endemic, immunization remains our best defense against severe outcomes. Emerging SARS-CoV-2 variants have fueled the need for improved prevention strategies. Furthermore, protection of the immunocompromised population remains a key challenge for clinicians. Bringing together the latest data from Asia and around the world, our panel of infectious disease experts bring you up to date with the key topics in the COVID-19 vaccine space.
  • To educate HCPs and vaccinators on the most comprehensive updates relating to COVID-19 vaccine effectiveness
  • To provide an exclusive update into real world evidence from Thailand demonstrating 3rd and 4th dose COVID-19 vaccine effectiveness
  • To understand the gaps in vaccine coverage and effectiveness, and to explore alternate ways to protect those most at risk.
Schedule Time Description/Title Speaker
1045 hrs Welcome and introduction Dr Bruce Mungall
1050 hrs Expert Global review of COVID-19 vaccine effectiveness Booster doses versus Omicron Prof Anna Ong-Lim
1105 hrs Third and fourth dose effectivenes s of COVID-19 vaccines in Chiang Mai, Thailand Prof Suwat Chariyalertsak
1125 hrs The unmet need in high-risk groups despite vaccination: Leaving no-one behind Dr Barnaby Young
1140 hrs Q&A

Prof Anna Ong-Lim (Philippines)

Dr Ong-Lim is a Professor of the University of the Philippines College of Medicine, Chief of the Infection and Tropical Disease Division of the UP Philippine General Hospital (UP PGH), and member of the DOH-Technical Advisory Group. She is also a fellow of both the Philippine Paediatric Society (PPS) and the Pediatric Infectious Disease Society of the Philippines (PIDSP). She serves as a member of the Board of Trustees of the PPS and is the current President of PIDSP.

Prof Suwat Chariyalertsak (Thailand)

Prof Chariyalertsak is the Dean of Faculty of Public Health, Chiang Mai University, and Leader of CMU HIV Prevention Clinical Research Site, Research Institute for Health Sciences, Chiang Mai University, Thailand.

He is also a Professor in the Department of Community Medicine at the Chiang Mai University Faculty of Medicine and holds an MPH of Health System Management from Tulane University and a Dr.PH. in Infectious Disease Epidemiology from Johns Hopkins University.

Dr Barnaby Young (Singapore)

Dr Young graduated from Cambridge University in 2005. After foundation medical postings in the UK he moved to Singapore in 2007 and undertook infectious diseases specialist training at the Communicable Disease Centre in Singapore from 2010 to 2014. He completed a Masters in Infectious Disease from the University of London and London School of Hygiene and Tropical Medicine in 2016. Dr Young studied for a PhD at the Lee Kong Chian School of Medicine, Nanyang Technological University from 2017-2021. His thesis, supervised by Prof Annelies Wilder-Smith and A/Prof Yeo Tsin Wen, investigates how to improve year-round protection against influenza in Singapore.

Title Healthy Aging: Vaccines For Life.
ASVAC 2021
Details Date: 17th September 2022
Time: 1045 – 1130 hrs, IST time (GMT +5.30)
Synopsis The COVID-19 pandemic has brought about an increased focus on immunization, especially in adults.
Join us in the upcoming symposium, where experts Dr Wickramasinghe, Dr Kassianos and Prof Badur will be discussing the increased risk and burden of disease of infectious diseases as we get older and how vaccinology can impact healthy aging. This will also include where we are today with adult vaccinology and future vaccine technologies, with an interactive Q and A section.
Objectives The main objective is to establish that adults are equally as vulnerable to Vaccine Preventable Diseases (VPDs) as children, the immunological challenges in adults and what the vaccination goal should be. We will discuss where we are today with adult vaccinology, establish the robust growth and future opportunities in adult vaccination including beyond individual protection to establish the indirect benefits from adult vaccination.
Schedule Time Description/Title Speaker
1045 hrs Welcome and Introduction Dr H. T. Wickramasinghe
(Sri Lanka)
1050 hrs Burden of VPDs in adults & elderly Dr George Kassianos
(United Kingdom)
1105 hrs Advancement in vaccinology: Increasing vaccine effectiveness in Adults & Elderly Prof Selim Badur
1120 hrs Q&A Dr H. T. Wickramasinghe
(Sri Lanka)

Dr H. T. Wickramasinghe (Sri Lanka)

Dr H T Wickramasinghe is the immediate president of the Vaccine and Infectious Diseases Forum of Sri Lanka. He is a Founder member of The Asian Society of Pediatric Infectious Diseases and the past president of The Asian Society of Pediatric Infectious Diseases in 2011-2012. He is also a member of the steering committee of the Immunization Partners of Asia Pacific (IPAP). He also served as a board member of The World Society of Pediatric Infectious Diseases from 2015 to 2019.

Dr George Kassianos (United Kingdom)

Dr George Kassianos is a trained GP, National Immunization Lead & Fellow of the Royal College of GPs, President of British Global and Travel Health Association (BGTHA) and Fellow of several international societies. He is Associate Editor of international journal, ‘Drugs in Context’, serves on numerous editorial boards and previously, Editor of other renowned medical journals.

He has published and lectured on influenza, Pneumococcal Infection, Herpes Zoster, Vaccination of older adults, among others.

Dr Kassianos was awarded the Royal College of GPs’ Foundation Council Award (2018) and appointed Commander of the Order of the British Empire by the Queen (2020).

Prof Selim Badur (Turkey)

Professor Selim Badur is the Global Director, Scientific Affairs & Public Health at GlaxoSmithKline Vaccines, with responsibility for high level scientific exchange with external experts and health authorities worldwide about Influenza and other viral vaccine, especially on countries from emerging economies. He joined GSK from the University of Istanbul- Faculty of Medicine where he was the director of Virology Department and coordinator of the National Reference Laboratory of Influenza-WHO.

Title Sustaining Immunization for Children in the Current Era.
ASVAC 2021
Details Date: 17 September 2022
Time: 1415 – 1515 hrs, IST time (GMT +5.30)
Synopsis Vaccination is considered as one of the most cost-effective public health measures available, very effectively reducing morbidity and mortality associated with various infectious diseases, especially in children. This symposium will look to understand how to optimize a national immunization program in the current context and recognizing the role and value of combination vaccines to protect in infancy. We will look at the challenges in childhood vaccination, perspectives for high protection in infancy and factors that may affect vaccine coverage rates (VCR). In the frame of the global polio eradication initiative (GPEI), it will be an opportunity to look to the perspective of wP based combination containing IPV vaccine and how it would fit in the existing primary series of IPV only schedule.
Objectives Overall objective:
Understand how to optimize a national immunization program in the current context and recognizing the role of combination vaccines to protect in infancy and in global polio eradication initiative.

Lecture 1:
  • Understand how to optimize a national immunization program in the current context and in the perspective
  • Childhood vaccination challenge & perspective for high protection
  • Look to factors affecting vaccine coverage rates (VCR)
  • Recognize the role of combination vaccines to protect in infancy

Lecture 2:
  • Perspective of combination containing IPV vaccine in the global polio eradication initiative (GPEI).
Schedule Time Description/Title Speaker
1415 hrs Opening and welcome Prof Anna Ong-Lim
1420 hrs Addressing the Challenges of Increasing Immunization Rates with Combination Vaccines Prof Federico Martinón-Torres
1445 hrs Global Polio Eradication Initiative: Role of wP combination containing IPV vaccine Dr Mouloud Khris
1505 hrs Q&A Prof Anna Ong-Lim

Prof Federico Martinón-Torres (Spain)

Prof Federico Martinón-Torres is a peadiatrician and clinical researcher currently practicing as the Head and Coordinator of the Pediatrics Department and Director of Clinical, Infectious and Translational Pediatrics, at the Hospital Clínico Universitario de Santiago (Spain). Aside he coordinates research work at Vaccine Research and Pediatric Clinical Trials Unit, Instituto de Investigación Sanitaria de Santiago and is the PI of the Genetics, Vaccines, Infections and Pediatrics Group ( Dr. Martinon-Torres is also the corresponding Academician of the Royal Academy of Medicine of Galicia and a Professor of Pediatrics, University of Santiago.
He has published over 700 papers (articles, books, chapters) with a personal impact factor > 2,000 (JCR 2020). He has delivered more than 600 lectures in national & international activities. His main research interests are: infectious diseases, vaccines, pneumococcal diseases, bronchiolitis, meningococcal disease and heliox therapy.

Dr Mouloud Khris (Morocco)

Medical doctor, currently global medical lead & expert disease Asia JPAC, Polio, Pertussis and Haemophilus influenzae type b vaccine, sanofi vaccine, during the 8 past years he has been leading sanofi pasteur vaccine medical affairs in diverse geographic territories, in North Africa, French & English-speaking Africa, working to develop public health, contributing to sustain and strengthen vaccination to save lives of people and the communities.

Prof Anna Ong-Lim (Philippines)

Prof Anna Ong-Lim is a pediatric infectious disease specialist, a professor and the division chief of the Infectious and Tropical Diseases, Department of Pediatrics at the University of the Philippines-Philippine General Hospital (UP-PGH). She serves as a member of the Board of Trustees of the Philippine Paediatric Society (PPS) and is a past President of Pediatric Infectious

Prof Ong-Lim was a member of the Department of Health's Technical Advisory Group, the Interagency Task Force (IATF) Technical Working Group on COVID-19 variants, and the Interim National Immunization Technical Advisory Group for COVID-19 vaccines as part of the Philippines' COVID-19 response. She was recently awarded the Order of Lapulapu, Rank of Magalong medal for having rendered extraordinary service and made exceptional contributions to the success of the COVID-19 response by providing accurate, up-to-date, and timely information on Covid 19 patient prevention and care.

She has also published extensively on pediatric health, pediatric vaccines and infectious diseases, and she has had several significant roles in clinical trials in the Philippines and throughout Asia.

Title Takeda Dengue Symposium: Latest Updates on Dengue
ASVAC 2021
Details Date: 17th September 2022
1415 – 1515 hrs, IST time (GMT+5.30)
1615 – 1715 hrs, HKT/SGT time (GMT+8)
Synopsis Dengue is the world’s most prevalent and important arboviral disease and ranks highly amongst new and emerging infectious diseases of public health significance. Dengue prevention through vaccination; which is one of the cost effective interventions known to mankind; remains the need of the hour.
This symposium would look at the current status of Dengue in Asian countries, its management and latest data available with TAK-003, a novel Dengue tetravalent vaccine candidate would also be addressed, key takeaways from the session and way forward with Dengue disease would be discussed.
Objectives To apprise the audience on the significance of Dengue as a disease of public health significance, discuss its clinical management and prevention through vaccination which is an unmet medical need.
Schedule Time Description/Title Speaker
1415 – 1420 hrs Welcome, Introduction of Speakers & Context Setting Dr Puneet Kalra
Therapy Area Lead - Takeda India/Sri Lanka
1420 – 1430 hrs Current status of Dengue in Sri Lanka and Asian countries Dr Neelika Malavige (Sri Lanka)
1430 – 1440 hrs Clinical Management of Dengue Dr A. LakKumar Fernando (Sri Lanka)
1440 - 1500 hrs Brief overview of Takeda Dengue vaccine (TAK -003) with 4.5 year data results Dr Vianney Tricou
Medical Director - Takeda VBU (Switzerland)
1500 – 1515 hrs Q &A
Key Takeaways & Way Forward

Dr. Puneet Kalra

  • Therapy Area Lead - India/Sri Lanka for Takeda Vaccines
  • Trained pediatrician with more than a decade of industry experience in Vaccines

Dr Neelika Malavige
MBBS, MRCP, FRCPath (UK), FRCP (Lond), D. Phil.(Oxon), FNAAS (SL), Member of ISID Executive Committee

  • Head of Dengue Global Programme and Scientific Affairs, DNDi
  • Immunologist and a well-recognized leader in the field of Dengue research

Dr A. LakKumar Fernando

  • Senior Consultant Pediatrician; Principal Investigator TIDES study Sri Lanka
  • Dengue expert and the Founder Clinical Head of the Centre for Clinical management of Dengue & DHF; Negombo Sri Lanka

Dr Vianney Tricou
PharmD (Lyon, France), PhD( Oxford, UK.)

  • Medical Director -Takeda's Vaccine Business Unit- Zurich, Switzerland
  • Involved in development of TAK-003, a novel dengue tetravalent vaccine candidate

18 September 2022, Sunday

Title Challenges and Prospects of Pneumococcal Prevention in Adults Within Asia Pacific
ASVAC 2021
Details Date: 18 September 2022
Time: 1045 – 1145 hrs, IST time (GMT +5.30)
1315 – 1415 hrs, HKT / SGT (GMT +8)
Synopsis Challenges and prospects of pneumococcal prevention in adults within Asia Pacific
Objectives To overview key considerations in pneumococcal prevention in adults; describe remaining challenges and future prospects of pneumococcal vaccination in adults; and to provide an overview of updated information about pneumococcal disease burden in the adult population of the Asia Pacific region
Schedule Time Description/Title Speaker
5 MINUTES Welcome and Introduction Prof Rontgene Solante (Philippines)
25 MINUTES Key Considerations in Pneumococcal Prevention in Adult Population and Future Prospects Prof Paul Van Buynder (Australia)
20 MINUTES Challenges and Prospects of Pneumococcal Prevention in Adults in the Asia Pacific Region Prof Terapong Tantawichien (Thailand)
10 MINUTES Panel discussion and Q&A Prof Rontgene Solante, Prof Paul Van Buynder, Prof Terapong Tantawichien
Closing remarks Prof Rontgene Solante (Philippines)

Prof Rontgene Solante (Philippines)

Prof Rontgene Solante is the Vice-President of the Philippine College of Physicians (PCP) and the Chair of Adult Infectious Diseases and Tropical Medicine San Lazaro Hospital. He is now a Professor at the Department of Medicine at UERMMMC College of Medicine and Chair of the Adult Infectious Diseases section. Previously, he was the President of the Philippine Society for Microbiology and Infectious Disease (PSMID).

Prof Paul Van Buynder (Australia)

Professor Van Buynder is a Public Health Physician who holds a Professorship in the School of Medicine at Griffith University, with a focus on vaccinology. He has worked in senior health positions in a number of Australian states, in Canada and in the Centre for Infections in London managing respiratory disease programs for the United Kingdom.
He is a registered expert with the International Federation of Aging and a past president of the Australian Immunisation Coalition.
His research interests are in new vaccines, vaccine hesitancy and the control of infectious diseases in aged care settings.
He is the author of over 70 book chapters and refereed journal articles.

Prof Terapong Tantawichien (Thailand)

Terapong Tantawichien is Professor, Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Thailand. He received his medical degree from Chulalongkorn University in 1987 and is board certified in Internal Medicine, Infectious Diseases and Preventive Medicine (Thailand). He began his teaching career in 1993 when he started teaching infectious diseases at Department of Medicine, Chulalongkorn University. He was President of Infectious Diseases Association of Thailand and Chairman, Department of Medicine, Chulalongkorn University. Presently he was chairman of Tropical Medicine Cluster, Chulalongkorn University and Assistant Director of Queen Saovabha Memorial Institute, Thai Red Cross Society. He was awarded the 1st Young Investigator Award from Infectious Diseases Association of Thailand in 2001 and Research Award from the Royal College of Physician of Thailand in 2014. His main scientific interests are rabies vaccination, adult immunization, adult dengue, travel medicine and infections in immunocompromised hosts.